APA (7th ed.) Citation

R, P., I, B., RA, F., AY, K., JM, K., MB, G., . . . AG, M. (2021). Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study. Frontiers in endocrinology, 12, 662865. https://doi.org/10.3389/fendo.2021.662865

Chicago Style (17th ed.) Citation

R, Pivonello, et al. "Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study." Frontiers in Endocrinology 12 (2021): 662865. https://doi.org/10.3389/fendo.2021.662865.

MLA (9th ed.) Citation

R, Pivonello, et al. "Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study." Frontiers in Endocrinology, vol. 12, 2021, p. 662865, https://doi.org/10.3389/fendo.2021.662865.